- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04589468
Forsker på effekten av trening på kreft
Fase 1a/b-utprøving av trening som avlyttingsterapi for primær høyrisikokreft
Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Lee Jones, MD
- Telefonnummer: 6262184673
- E-post: leejones@coh.org
Studiesteder
-
-
California
-
Durate, California, Forente stater, 91010
- Rekruttering
- City of Hope Medical Center
-
Ta kontakt med:
- Lee Jones, MD
- Telefonnummer: 6262184673
- E-post: leejones@coh.org
-
Hovedetterforsker:
- Lee Jones, MD
-
San Carlos, California, Forente stater, 94070
- Har ikke rekruttert ennå
- Natera, Inc. (Data or Specimen Analysis Only)
-
Ta kontakt med:
- Shifra Krinshpun
- Telefonnummer: 510-826-3572
-
-
New Jersey
-
Basking Ridge, New Jersey, Forente stater, 07920
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
Middletown, New Jersey, Forente stater, 07748
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Montvale, New Jersey, Forente stater, 07645
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
-
New York
-
Commack, New York, Forente stater, 11725
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Commack (Limited Protocol Activities)
-
Harrison, New York, Forente stater, 10604
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
New York, New York, Forente stater, 10065
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Forente stater, 11553
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following:
° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a)
-
Stage 3 or
-
ctDNA positive
° High-risk breast cancer
-
Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT),
-
Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative,
-
CPS-EG score ≥ 3,
-
CPS-EG score ≥2 w ith ypN+, or
-
Recurrence score ≥ 25
-
No evidence of disease
-
Age ≥ 18
-
Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy
-
Non-exercising (i.e., < 30 minutes of moderate and < 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry)
° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI.
-
Cleared for exercise participation as per screening clearance via PAR-Q+
-
Willingness to comply with all study-related procedures
Exclusion Criteria:
- Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes
- Any other current diagnosis of invasive cancer of any kind
- Distant metastatic malignancy of any kind
- Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose-Finding/Escalation
Fifty (n=50) post-treatment patients with colorectal cancer or breast cancer, deemed high-risk of relapse. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial. |
Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial. |
|
Eksperimentell: Dose Expansion
An independent cohort of 30 post-treatment patients with colorectal (n=15) or breast (n=15) cancer deemed high-risk of relapse. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D. |
Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b.
Tidsramme: 24 weeks
|
Using an adaptive phase 1 (non-randomized) design, non-exercising (i.e., <60 mins/wk of moderate or vigorous exercise) post-treatment patients with primary breast, prostate, or colorectal cancer and detectable ctDNA (n=50) will be administered one of five escalating dose levels. |
24 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Lee Jones, MD, City of Hope Medical Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Prostata sykdommer
- Mannlige urogenitale sykdommer
- Tarmsykdommer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolonsykdommer
- Hudsykdommer
- Bryst sykdommer
- Oppførsel
- Hud- og bindevevssykdommer
- Prostatiske neoplasmer
- Kolorektale neoplasmer
- Brystneoplasmer
- Motorisk aktivitet
- Motorisk aktivitet
- Bevegelse
- Muskel- og skjelettfysiologiske fenomener
- Muskel- og skjelett og nevrale fysiologiske fenomener
- Øvelse
Andre studie-ID-numre
- 25779
- P30CA033572 (U.S. NIH-stipend/kontrakt)
- 25779 (Annen identifikator: City of Hope Medical Center)
- NCI-2026-04201 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .